Creutzfeldt-Jakob disease

Among prion diseases, Creutzfeldt-Jakob disease is a neurodegenerative disorder primarily characterized by dementia and balance problems. The disease progresses rapidly and is invariably fatal.

Our Mission

  • Monitoring the epidemiological trends of Creutzfeldt-Jakob disease in collaboration with the National Creutzfeldt-Jakob Disease Surveillance Network (RSN-MCJ)

  • Informing the general public

  • Provide insights to health authorities

Data

View data on the epidemiological situation of Creutzfeldt-Jakob disease in France on Santé publique France

The surveillance system for Creutzfeldt-Jakob disease, based on mandatory reporting and notifications to the RNS-CJD, makes it possible to track the progression of this disease

The emergence of the variant form of CJD and its link to bovine spongiform encephalopathy (BSE)

Following the discovery that the prion responsible for variant Creutzfeldt-Jakob disease (incorrectly referred to as the “mad cow crisis”) can be transmitted through food derived from animal products, 28 confirmed or probable cases of CJD were identified in France, with patients dying between 1992 and 2019 (table).

These included 12 men and 16 women. The median age at death or diagnosis was 36 years (ranging from 19 to 58 years). Among them, 9 people resided in the Île-de-France region and 19 in other regions. All cases identified to date were Met-Met homozygous for codon 129 of the prion protein gene (PRNP); they had no identified risk factors for other recognized forms of CJD. One case had visited the United Kingdom very regularly for about ten years starting in 1987.

Number of confirmed or probable CJD deaths in France (updated January 31, 2026)

Year Suspected cases Sporadic CJD Growth hormone-induced iatrogenic CJD Other iatrogenic CJD Genetic CJD Confirmed or probable v-CJD, deceased Probable vCJD, not deceased Total CJD
1992 71 38 7 2 4 0 0 51
1993 63 35 12 1 7 0 0 55
1994 90 45 5 3 7 0 0 60
1995 112 59 8 1 6 0 0 74
1996 200 68 10 0 10 1 0 89
1997 296 80 6 1 5 0 0 92
1998 457 81 8 1 13 0 0 103
1999 589 92 8 0 5 0 0 105
2000 823 88 9 0 8 1 0 106
2001 1,100 109 5 0 15 1 0 130
2002 1044 107 2 2 13 3 0 127
2003 1084 108 8 1 10 0 0 127
2004 884 98 8 0 9 2 0 117
2005 925 82 4 1 10 6 0 103
2006 1314 124 5 0 8 6 0 143
2007 1,372 138 1 0 15 3 0 157
2008 1475 105 5 0 12 0 0 122
2009 1,485 114 4 0 14 2 0 134
2010 1614 151 0 0 10 0 0 161
2011 1609 115 0 0 6 0 0 121
2012 1693 131 0 1 11 0 0 143
2013 1744 124 0 0 6 1 0 131
2014 1721 150 0 0 16 1 0 167
2015 1959 131 1 0 8 0 0 140
2016 1952 140 0 0 12 0 0 152
2017 2091 145 1 0 21 0 0 167
2018 2025 161 0 0 12 0 0 173
2019 1974 154 1 0 9 1 0 165
2020 1919 121 0 0 7 0 0 128
2021 2147 135 1 0 10 1 0 147
2022 2156 125 0 0 10 0 0 135
2023 2303 91 0 0 10 0 0 101
2024 1928 85 0 0 8 0 0 93
2025 1892 71 0 0 2 0 0 73
2026 84 1 0 0 0 0 0 1

Four iatrogenic CJD deaths caused by recombinant growth hormone occurred in 1991.

An overall increase in the incidence of Creutzfeldt-Jakob disease between 1992 and 2002

The primary explanation for the steady increase in the incidence of sporadic Creutzfeldt-Jakob disease is the implementation of active surveillance. The two “mad cow” crises (1996 and 2000) and the development of the 14.3.3 test (1997) likely also contributed to better case identification, particularly among the elderly. This increase has, in fact, been observed in all countries within the EuroCJD active surveillance network.